Theravance Biopharma Income Statement (2013-2025) | TBPH

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	14.26M	12.91M	13.19M	14.95M	2.50M	11.05M	12.45M	14.65M	10.42M	13.75M	15.69M	17.57M	14.50M	14.26M	16.87M	18.75M	15.39M	26.20M	19.99M	25.00M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)	67.60M	51.09M	43.74M	31.23M	23.25M	14.92M	9.87M	15.35M	14.57M	9.43M	8.31M	8.31M	8.97M	9.95M	9.27M	9.45M	11.45M	10.49M	8.11M	7.36M
Selling, General & Administrative (Quarter)	30.55M	25.93M	21.30M	21.52M	17.84M	16.22M	16.28M	16.73M	19.18M	19.28M	16.14M	15.49M	16.74M	17.06M	16.88M	18.50M	18.37M	18.43M	18.33M	18.52M
Restructuring Costs (Quarter)			15.40M	18.37M	9.32M	3.00M	33.00M		1.57M	1.17M
Other Operating Expenses (Quarter)			-13.63M		1.28M	3.78M	-37.55M	0.00M						2.95M	1.56M					-0.00M
Operating Expenses (Quarter)	98.15M	77.02M	66.81M	71.11M	51.70M	37.93M	21.59M	32.08M	35.33M	29.87M	24.45M	23.80M	25.71M	29.96M	27.70M	27.95M	29.82M	28.92M	26.45M	25.88M
Operating Income (Quarter)	-83.89M	-64.11M	-53.62M	-56.17M	-38.50M	-26.88M	-9.14M	-17.43M	-24.91M	-16.12M	-8.76M	-6.24M	-11.21M	-15.71M	-10.84M	-9.20M	-14.43M	-2.73M	-6.46M	20.01M
EBIT (Quarter)	-83.89M	-64.11M	-53.62M	-56.17M	-38.50M	-26.88M	-9.14M	-17.43M	-24.91M	-16.12M	-8.76M	-6.24M	-11.21M	-15.71M	-10.84M	-9.20M	-14.43M	-2.73M	-6.46M	20.01M
Non-operating items
Other Non Operating Income (Quarter)	-0.23M	1.17M	-0.17M	0.34M	-0.38M	2.44M	2.76M	11.58M	2.98M	2.50M	1.79M	1.85M	1.43M	1.13M	1.42M	0.90M	0.94M	1.46M	4.14M	3.64M
Non Operating Income (Quarter)	-0.23M	1.17M	-0.17M	0.34M	-0.38M	2.44M	2.76M	3.72M	2.98M	2.50M	1.79M	1.85M	1.43M	1.13M	1.42M	0.90M	0.94M	1.46M	4.14M	3.64M
Net income details
EBT (Quarter)	-79.45M	-52.62M	-55.92M	-57.97M	-39.73M	-22.80M	-16.02M	-14.26M	-22.48M	-14.19M	-7.58M	-5.02M	-10.40M	-15.22M	-10.05M	-10.95M	-14.14M	73.21M	-2.89M	-35.32M
Tax Provisions (Quarter)	0.23M	-0.22M	-0.01M	-0.20M	0.52M	-0.01M	-0.51M	-0.00M	-0.40M	1.46M	1.37M	3.49M	1.26M	1.31M	2.65M	6.59M	-0.56M	18.37M	-6.50M	23.57M
Profit After Tax (Quarter)	-79.68M	-52.41M	-55.91M	-57.81M	-41.54M	-8.19M	916.63M	-14.26M	-22.09M	-15.64M	-8.95M	-8.51M	-11.66M	-16.53M	-12.70M	-15.53M	-13.58M	54.84M	3.62M	61.02M
Equity Income (Quarter)	16.55M	21.93M	30.21M	35.31M	25.11M	28.13M
Income from Continuing Operations (Quarter)	-79.68M	-52.41M	-55.91M	-57.77M	-40.26M	-22.79M	-15.52M	-14.26M	-22.09M	-15.64M	-8.95M	-8.51M	-11.66M	-16.53M	-12.70M	-17.54M	-13.58M	54.84M	3.61M	-58.89M
Consolidated Net Income (Quarter)	6.81M	12.45M	20.60M	25.78M	15.59M	18.38M	927.09M	3.89M	-22.09M	-15.64M	-8.95M	-8.51M	-11.66M	-16.53M	-12.70M	-17.54M	-13.58M	54.84M	3.61M	-58.89M
Income towards Parent Company (Quarter)	6.81M	12.45M	20.60M	25.78M	15.59M	18.38M	927.09M	3.89M	-22.09M	-15.64M	-8.95M	-8.51M	-11.66M	-16.53M	-12.70M	-17.54M	-13.58M	54.84M	3.61M	-58.89M
Net Income towards Common Stockholders (Quarter)	6.81M	12.45M	20.60M	25.78M	15.59M	18.38M	927.09M	3.89M	-22.09M	-15.64M	-8.95M	-8.51M	-11.66M	-16.53M	-12.70M	-17.54M	-13.58M	54.84M	3.61M	-58.89M
Additional items
EPS (Basic) (Quarter)	-1.24	-0.80	-0.48	-0.43	-0.34	-0.35	12.14	-0.15	-0.35	-0.28	-0.17	-0.17	-0.24	-0.34	-0.26	-0.31	-0.27	1.09	0.07	1.20
EPS (Weighted Average and Diluted) (Quarter)	-1.24	-0.99	-0.48	-0.43	-0.55	-0.35	12.14	-0.21	-0.35	-0.28	-0.17	-0.17	-0.24	-0.34	-0.26	-0.31	-0.27	1.08	0.07	1.15
Shares Outstanding (Weighted Average) (Quarter)	64.49M	65.67M	67.94M	69.46M	75.25M	76.27M	75.68M	73.59M	62.93M	56.68M	52.36M	55.30M	48.28M	48.52M	48.69M	48.85M	49.71M	50.18M	50.52M	50.32M
Shares Outstanding (Diluted Average) (Quarter)	64.49M	65.67M	73.57M	69.46M	75.25M	76.27M	75.68M	73.59M	62.93M	56.68M	52.36M	55.30M	48.28M	48.52M	48.69M	48.85M	49.71M	50.73M
EBITDA (Quarter)	-79.71M	-52.41M	-35.30M	-56.17M	-25.97M	-8.21M	916.55M	-17.43M	-22.02M	-15.98M	-8.89M	-6.24M	-11.64M	-16.51M	-12.63M	-9.20M	-13.59M	54.83M	3.66M	20.01M
Interest Expenses (Quarter)	11.87M	11.61M	2.14M	2.14M	2.14M	2.14M	1.54M	0.55M	0.55M	0.57M	0.61M	0.62M	0.63M	0.64M	0.63M	0.64M	0.64M	0.66M	0.57M	0.58M
Tax Rate (Quarter)	-0.29%	0.42%	0.01%	0.35%	-1.32%	0.02%	3.16%	0.02%	1.76%	-10.28%	-18.03%	-69.66%	-12.13%	-8.59%	-26.32%	-60.15%	3.95%	25.09%	224.99%	-66.73%

Research Tools

Theravance Biopharma Income Statement (2013-2025) | TBPH

Create an account

Sign In

Reset Password